CASE REPORT / ПРИКАЗ БОЛЕСНИКА

Two-stage surgery for a large ventricular septal defect and patent ductus arteriosus associated with severe pulmonary arterial hypertension in an adult patient

Milan Đukić1,2, Stefan A. Đorđević1,2, Slobodan Ilić1,3, Igor Stefanović1,2, Dimitra Kalimanovska-Oštrić1,4
1University of Belgrade, Faculty of Medicine, Belgrade, Serbia; 2University Children’s Hospital, Department of Cardiology, Belgrade, Serbia; 3University Children’s Hospital, Department of Cardiac Surgery, Belgrade, Serbia; 4Clinical Center of Serbia, Department of Cardiology, Belgrade, Serbia

SUMMARY

Introduction Adult patients with pulmonary arterial hypertension (PAH) associated with congenital left-to-right shunting are often considered inoperable. Case outline A 26-year-old man presented with effort intolerance and palpitations. The diagnosis of PAH in the presence of a large perimembranous ventricular septal defect (VSD) and patent ductus arteriosus (PDA) was established. The patient was managed with a two-stage surgical approach involving an initial ligation of PDA, followed by VSD closure using unidirectional valved patch. Treatment decisions were based on the results of both invasive and non-invasive investigations. At follow-up, the patient was asymptomatic with pulmonary arterial pressure and vascular resistance returning to normal levels. Conclusion There is a possibility for an adult patient to have a congenital heart disease associated with marked pulmonary overcirculation that is still amenable to surgical repair. This implies that there is an individual response to a long-standing left-to-right shunt, and that the therapy should be considered on a case-by-case basis. Keywords: congenital heart defects; pulmonary hypertension; cardiac surgical procedures; adults

INTRODUCTION

Pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD) comprises a heterogeneous group of disorders characterized by the presence of pulmonary arterial hypertension in the setting of repaired or un repaired congenital systemic to pulmonary shunts [1, 2, 3]. PAH is fairly common in adult patients with CHD, and is associated with significant morbidity and mortality. The evidence regarding the management of PAH and CHD is scarce. The severity of PAH, the magnitude of the shunt, and the degree of vasoreactivity of the pulmonary circulation are key considerations in determining whether the condition is amenable to surgical treatment [4, 5, 6].

CASE REPORT

A 26-year-old man, 183 cm tall and weighing 65 kg, presented with effort intolerance and heart palpitations. His symptoms were consistent with NYHA functional class II. The patient was known for having a ventricular septal defect (VSD) and patent ductus arteriosus (PDA) diagnosed at birth. However, his parents did not consent to proposed surgical treatment at that time.

During a physical examination, there was an accentuated pulmonary component of the second heart sound, systolic murmur grade 2 over the precordium, and transcutaneous oxygen saturation of 96% on room air.

Chest X-ray showed significant cardiomegaly (cardiothoracic ratio of 0.62) with increased pulmonary vascular markings and clear lung fields.

Transthoracic echocardiogram revealed a large perimembranous-outlet VSD measuring 25 mm in diameter with no pressure gradient (PG) across it, and a widely opened PDA without transductal gradient. Left heart was dilated with a mildly impaired left ventricular systolic function (Table 1). There was an estimated pressure gradient of 78 mmHg across the tricuspid valve.

ECG showed extreme axis deviation, signs of biventricular hypertrophy, right bundle branch block, and biphasic T waves in the left-sided leads. A 24-hour Holter ECG monitoring revealed isolated ventricular extrasystoles.

Cardiac catheterization was performed to obtain hemodynamic data. Mean pulmonary arterial pressure (mPAP) was measured at 59 mmHg and there was a significant left-to-right shunt with a pulmonary to systemic blood flow ratio (Qp/Qs) of 2.1, pulmonary vascular resistance index (PVRI) of 6.8 WU/m², and pulmo-
Table 1. Echocardiographic data

| Echocardiographic parameter | at presentation | 18 months after the PDA ligation | 15 months after the VSD closure |
|-----------------------------|----------------|---------------------------------|--------------------------------|
| LVEDD/LVESD (mm)            | 67/49          | 68/41                           | 53/34                          |
| Left ventricular FS         | 0.27           | 0.40                            | 0.36                           |
| Left atrial diameter (mm)   | 52             | 42                              | 40                             |
| Tricuspid regurgitation gradient (mmHg) | 78            | 65                              | N/A                            |
| Pressure gradient across the VSD (mmHg) | no gradient | 45                              | 68                             |

LVEDD – left ventricular end-diastolic dimension; LVESD – left ventricular end-systolic dimension; FS – fractional shortening; TR – tricuspid regurgitation; VSD – ventricular septal defect

Table 2. Hemodynamic data obtained at cardiac catheterization

| Catheterization data | at presentation | 4 months after the PDA ligation | 17 months after the VSD closure |
|----------------------|----------------|---------------------------------|--------------------------------|
| Systolic/diastolic/mean PAP (mmHg) | 93/30/59       | 73/29/48                        | 34/11/19                       |
| Mean right atrial pressure (mmHg) | 13             | 8                               | 4                              |
| Systolic/diastolic/mean SAP (mmHg) | 95/54/77       | 95/68/80                        | 115/62/80                      |
| mPAP/mSAP             | 0.77           | 0.60                            | 0.24                           |
| Qp/Qs                 | 2.1            | 2.3                             | 1.2                            |
| PVR/5VR               | 0.37           | 0.21                            | 0.09                           |
| PVR (WU/m²)           | 6.8            | 5.1                             | 1.9                            |

PAP – pulmonary arterial pressure; SAP – systemic arterial pressure; mPAP/mSAP – the mean pulmonary arterial-to-systemic pressure ratio; Qp/Qs – pulmonary to systemic blood flow ratio; PVR – pulmonary vascular resistance index; PVRI/SVR – pulmonary to systemic vascular resistance ratio

nary to systemic vascular resistance ratio (PVR/SVR) of 0.37 (Table 2). Testing of pulmonary vasoreactivity to 100% oxygen inhalation bore no significant pressure reduction in the pulmonary artery.

Given the presence of both VSD and PDA in association with near systemic PAH, there was an issue of appropriate management strategy. However, considering the increased pulmonary blood flow, dilated left cardiac chambers, and PVRI less than 8 WU/m², we opted for surgical repair. It was decided to perform a two-stage surgery involving PDA ligation as an initial procedure, followed by VSD closure in case of drop in pulmonary vascular resistance.

First, the large PDA of 15 mm in diameter was ligated. To note, the patient did not receive pulmonary vasodilators perioperatively because they were not available at that time. Echocardiographic evaluation was performed on postoperative day one and ten, three months, one year, and eighteen months after the plication (Table 1) as defined by Novick et al. [7, 8]. A 5 mm fenestration was made in the primary VSD patch, and flap valve patch was created from bovine pericardial patch. Postoperative course was uneventful. The patient was started on mechanical ventilation with nitric oxide and oral Sildenafil on post-operative day one. He was weaned from mechanical ventilation on post-operative day two. Follow-up echocardiograms were performed on postoperative day one and ten, three months, one year, and 15 months after the VSD closure.

A repeat cardiac catheterization was undertaken 17 months following the last operation (Table 2). This verified that pulmonary vascular resistance and pressures returned to normal levels. Furthermore, it showed a minimal left-to-right shunting across the valve patch. At 15-month follow-up, there was a residual pressure gradient of 68 mmHg across the fenestrated patch (Table 1).

A repeat cardiac catheterization was undertaken 17 months following the last operation (Table 2). This verified that pulmonary vascular resistance and pressures returned to normal levels. Furthermore, it showed a minimal left-to-right shunting across the valve patch. At 15-month follow-up, there was a residual pressure gradient of 68 mmHg across the fenestrated patch (Table 1).

DISCUSSION

The rate of progression of pulmonary vascular disease depends on the size and location of the underlying cardiac defect, the amount of left-to-right shunting, previous surgical repair, and genetic factors [9]. Ventricular septal defects are the single most common lesions causing PAH. It is estimated that 10% of all VSDs and 50% of large VSDs have the potential to cause Eisenmenger syndrome if not repaired by the age of two [10]. In addition, Eisenmenger syndrome is more likely to develop in patients with large aortopulmonary or interventricular shunts [11].

DOI: https://doi.org/10.2298/SARH170720186D

Srp Arh Celok Lek. 2018 Nov-Dec;146(11-12):677-680
While there are some data regarding surgical repair for PAH-CHD in adults, very little is known about the long-term outcome of defect closure in this patient group [12, 13, 14].

In this report, we aimed to describe a management strategy for a symptomatic adult patient with severe PAH in the setting of a significant pulmonary overcirculation. The main rationale for considering the suitability for surgical repair was the presence of dilated left heart chambers, significant left-to-right shunt, and absence of cyanosis [4]. There was, however, a high pulmonary vascular resistance (PVR/SVR ratio of 0.37, PVRI 6.8 WU/m²). According to the now available guidelines, the patient was in the, so-called, grey zone of operability. In such cases the value of pulmonary arterial pressure and the PVR/SVR ratio, as well as the degree of pulmonary vasoreactivity, may guide clinicians in choosing patients who would benefit from surgical treatment [2, 4, 5, 12, 15].

The INOP test I was a multicenter study that gathered data on preoperative hemodynamics, including pulmonary vascular response to oxygen and NO, in patients with PAH-CHD (PVR/SVR ≥ 0.33). A PVR/SVR ratio of less than 0.42 and 0.27 with the use of oxygen alone and oxygen plus nitrogen oxide, respectively, was identified as an optimal cut-off value for determining operability (reduced risk of death or right ventricular failure after surgery) [6]. Some authors recommend that a course of selective pulmonary vasodilators be used for a sufficient period of time with subsequent assessment of response to this therapy before carrying out surgical repair for CHD [16].

There are several reports on partial closure of VSD in patients with severe PAH using a UVP [7, 8, 17–20]. During periods of acute elevation of pulmonary arterial pressure, valve opening allows blood flow from right to left. This right-to-left shunt prevents acute right ventricular failure that could be caused by refractory PAH and helps in maintaining adequate cardiac output, thus reducing the risk of early postoperative death. Therefore, unidirectional flap valve patch should enable low-risk VSD closure in the presence of pronounced, but potentially reversible, PAH [7, 8, 12].

In conclusion, evidence-based data on the management of pulmonary hypertension in adult patients with unrepaired CHD and significant left-to-right shunting are scarce. The literature, moreover, is lacking with regard to long-term outcome. The treatment approach should be individualized based on clinical presentation and the results of non-invasive and invasive investigations, including cardiac catheterization and pulmonary vasoreactivity testing.

Our report shows that normal pulmonary hemodynamics can be established in a patient with a long-standing PAH-CHD with a stepwise surgical repair. Furthermore, both short-term and long-term postoperative outcome might be favorable.

REFERENCES

1. ReferencesD’Alto M, Mahadevan VS. Pulmonary arterial hypertension associated with congenital heart disease. Eur Respir Rev. 2012; 21(126):328–37.
2. Simonneau G, Gatzoulis MA, Adatia I, Celerier D, Denton C, Ghofrani A, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013; 62(25 Suppl):D34–41.
3. Lau EM, Humber M. A critical appraisal of the updated 2014 Nice Pulmonary Hypertension Classification System. Can J Cardiol. 2015; 31(4):367–74.
4. Wames CA, Williams KG, Bashore TM, Child JS, Connolly HM, Dearani JA, et al. ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease). Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008; 52(23):e143–263.
5. Galliè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015; 46(4):903–75.
6. Balzer DT, Kort HW, Day RW, Corneli HM, Kovalchin JP, Cannon BC, et al. Inhaled Nitric Oxide as a Preoperative Test (INOP Test I): the INOP Test Study Group. Circulation. 2002; 106(12 Suppl 1):76–81.
7. Novick WM, Gurbuz AT, Watson DC, Lazorishinets VV, Perepeka AN, Malcić I, et al. Double Patch Closure of Ventricular Septal Defect With Increased Pulmonary Vascular Resistance. Ann Thorac Surg. 1998; 66(5):1533–7.
8. Novick WM, Sandoval N, Lazorhysynets VV, Castillo V, Baskevitch A, Mo X, et al. Flap valve double patch closure of ventricular septal defects in children with increased pulmonary vascular resistance. Ann Thorac Surg. 2005; 79(1):21–8.
9. Du L, Sullivan CC, Chu D, Cho AJ, Kido M, Wolf PL, et al. Signaling molecules in nonfamilial pulmonary hypertension. N Engl J Med. 2003; 348(6):500–9.
10. Hoffman JI, Kaplan S, Liberthson RR. Prevalence of congenital heart disease. Am Heart J. 2004; 147(3):425–39.
11. Kaemmerer H, Mebus S, Schulze-Neick I, Eicken A, Trindade PT, Hager A. The Adult Patient with Eisenmenger Syndrome: A Medical Update After Dana Point Part I: Epidemiology, Clinical Aspects and Diagnostic Options. Curr Cardiol Rev. 2010; 6(4):343–55.
12. Talwar S, Keshri VK, Choudhary SK, Gupta SK, Ramakrishnan S, Saxena A, et al. Unidirectional valved patch closure of ventricular septal defects with severe pulmonary arterial hypertension: hemodynamic outcomes. J Thorac Cardiovasc Surg. 2014; 148(6):2570–5.
13. Talwar S, Keshri VK, Choudhary SK, Gupta SK, Ramakrishnan S, Juneja R, et al. Surgical strategies for patients with congenital heart disease and severe pulmonary hypertension in low/middle-income countries. Heart Asia. 2015; 7(2):31–7.
14. Gan HL, Zhang JQ, Zhang ZG, Luo Y, Zhou QW, Bo P. The unidirectional valve patch provides no benefits to early and long-term survival in patients with ventricular septal defect and severe pulmonary artery hypertension. J Thorac Cardiovasc Surg. 2010; 139(4):950–5.
15. Post MC, Jansens S, Van de Werf F, Budts W. Responsiveness to inhaled nitric oxide is a predictor for mid-term survival in adult patients with congenital heart defects and pulmonary arterial hypertension. Eur Heart J. 2004; 25(18):1651–6.
16. Beghetti M, Galie N, Bonnet D. Can “inoperable” congenital heart defects become operable in patients with pulmonary arterial hypertension? Dream or reality? Congenit Heart Dis. 2012; 7(1):3–11.
17. Zhou Q, Lai Y, Wei H, Song R, Wu Y, Zhang H. Unidirectional valve patch for repair of cardiac septal defects with pulmonary hypertension. Ann Thorac Surg. 2005; 79(6):1245–8.
18. Zhang B, Wu S, Liang J, Zhang G, Jiang G, Zhou M, et al. Unidirectional monovalve homologous aortic patch for repair of ventricular septal defect with pulmonary hypertension. Ann Thorac Surg. 2007; 83(6):2176–81.
19. Rao PS, Raju V, Narayana M. Flap valved closure of ventricular septal defects with increased pulmonary vascular resistance. Interact Cardiovasc Thorac Surg. 2010; 11(5):577–80.
20. Talwar S, Choudhary SK, Garg S, Saxena A, Ramakrishnan S, KoIthari SS, et al. Unidirectional valved patch closure of ventricular septal defects with severe pulmonary arterial hypertension. Interact Cardiovasc Thorac Surg. 2012; 14(6):699–702.

САЖЕТАК
Увод
Одрасли болесници са урођеним срчаним манама са лево-десним шантом и придруженом плућном артеријском хипертензијом често се сматрају иноперабилним.

Приказ болесника
Двадесетшестогодишњи мушкарац долази на преглед због појачаног замарања при напору и осећаја лупања срца. Постављена му је дијагноза великог перимембранозног дефекта међукоморске преграде, отвореног артеријског канала и придруженог тешког плућног шантра и плућне артеријске хипертензије. Срчансу ману операцијом у две етапе: прво је утицај на соковне функције и на теснину плућног шантра у току првих новембра 2014, а после је утицај на соковне функције и брзину прелаза крви кроз плућна артерија. У току рада утора отворену артеријску дефект преграда ограничишћеме на правом делу плућне артерије. Током остатка ове етапе резултати неинвазивних и инвазивних испитивања показали су нормални ниво притиска у плућној артерији и плућна васкуларна резистенција. Болесник није имао тегоба.

Закључак
Постоји могућност да одрасла особа има урођену срчану ману са значајно повећаним протоком крви кроз плућа, која се још увек може успешно кориговати хируршком интервенцијом. Током тешког плућног шантра и плућне артеријске хипертензије операција је могућа затворања дефекта плућне артерије и критичких зона срца, која је била одлуком носмерни вентил. Одлуке о лечењу су биле засноване на налазима неинвазивних и инвазивних испитивања. Током праћења притисак у плућној артерији и плућна васкуларна резистенција су се враћали на нормалан ниво, а болесник није имао тегоба.

Кључне речи: урођене срчане мане; плућна хипертензија; кардиохируршке операције; одрасли